Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

By Lieping Chen, Xue Han. Journal of Clinical Investigation, 2015

1,205 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/cc4e9a2bc6d541e3b8fe6b9b29a3dfb1e63089ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Hung
2. Yiping Yang
3. J. Hsu
4. Chia‐Wei Li
5. Jong-Ho Cha
6. Li-Chuan Chan

In Oncology

1. M. Hung
2. Yiping Yang
3. J. Hsu
4. Chia‐Wei Li
5. Jong-Ho Cha
6. Li-Chuan Chan

Citations in the corpus

• Metformin promotes antitumor immunity via endoplasmic reticulum-associated degradation of PD-L1 (2018, neutral): “the attractive target for cancer immunotherapy (Chen and Han, 2015).”
• Mechanisms controlling PD-L1 expression in cancer (2019, background): “However, cancer cells also hijack the inflammatory pathways (adaptive signaling pathway) to enhance PD-L1 expression and create favorable conditions for tumor progression by suppressing anti-tumor immunity (Chen and Han, 2015; Topalian et al., 2015).”
• Cancer immunotherapy: harnessing the immune system to battle cancer. (2015, background): “The Review by Chen and Han focuses on the history and current developments of anti–PD-1 therapy (22).”
• PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “The clinical activity of anti-PD-1and PD-L1 mAbs holds promise in targeting PD-1 and PD-L1 immune checkpoints, thereby ameliorating patient conditions significantly (Chen and Han, 2015).”